Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma

European Journal of Ophthalmology

Volumn 22, Issue 1, 2011, Pages 34-44

  Gandolfi, Stefano ^a   Paredes, Tania ^b   Goldberg, Ivan ^c   Coote, Michael ^d   Wells, Anthony ^e   Volksone, Lasma ^f   Pillai, Manju R ^g   Stalmans, Ingeborg ^h   Denis, Philippe ⁱ  

^a UNIVERSITY OF PARMA   (Italy)

^b Tratamiento de las Enfermedades Reumáticas S C CLIDITER   (Mexico)

^c Eye Associates   (Australia)

^d Melbourne Eye Specialists ^*  (Australia)

^e Capital Eye Specialists   (New Zealand)

^f RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^g ARAVIND EYE HOSPITAL   (India)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Benzalkonium chloride; Glaucoma; Ocular hypertension; Polyquaternium 1; Travoprost

Indexed keywords

BENZALKONIUM CHLORIDE; POLIDRONIUM CHLORIDE; PRESERVATIVE; TRAVOPROST;

ABDOMINAL MASS; ADULT; AGED; ARTICLE; ASTHENOPIA; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EVENING DOSAGE; EYE IRRITATION; EYE PAIN; FEMALE; FOLLOW UP; FOREIGN BODY; FOREIGN BODY SENSATION; HUMAN; HYPEREMIA; HYPERPIGMENTATION; IMMUNOPATHOLOGY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE LOWERING EFFECT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OCULAR HYPEREMIA; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SKIN DISCOLORATION; SKIN DISEASE; SOFT TISSUE DISEASE; SUBCUTANEOUS TISSUE DISORDER;

AGED; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CLOPROSTENOL; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; POLYMERS; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 80054794909     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000001     Document Type: Article

References (34)

1. Friedman DS, Wolfs RC, O'Colmain BJ, et al, Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004; 122: 532-8.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-7.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13; discussion 829-30.
4. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
5. Fellman RL, Sullivan EK, Ratliff M, et al, Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002; 109: 998-1008.
6. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 2008; 17: 217-22.
7. Netland PA, Landry T, Sullivan EK, et al, Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-84.
8. Orengo-Nania S, Landry T, Von Tress M, Silver LH, Weiner A, Davis AA, Travoprost Study Group. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001; 132: 860-8.
9. de Jong C, Stolwijk T, Kuppens E, de Keizer R, van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol 1994; 232: 221-4.
10. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003; 12: 486-90.
11. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29: 312-34.
12. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma 2003; 12: 480-5.
13. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proin-flammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004; 45: 1360-8.
14. Epstein S P, Chen D, Asbell PA. Evaluation of biomarkers of inflammation in response to benzalkonium chloride on cor-neal and conjunctival epithelial cells. J Ocul Pharmacol Ther 2009; 25: 415-24.
15. Kahook MY, Noecker RJ. Comparison of corneal and con-junctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008; 27: 339-43.
16. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol 2009; 3: 291-5.
17. Kusano M, Uematsu M, Kumagami T, Sasaki H, Kitaoka T. Evaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivo. Cornea 2010; 29: 80-5.
18. Uematsu M, Kumagami T, Kusano M, et al. Acute corneal epithelial change after instillation of benzalkonium chloride evaluated using a newly developed in vivo corneal transepi-thelial electric resistance measurement method. Ophthalmic Res 2007; 39: 308-14.
19. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994; 112: 1446-54.
20. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 2007; 18: 134-9.
21. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009; 18: 293-300.
22. Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily tra-voprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007; 17: 183-90.
23. Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Pre-operative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology 2010; 117: 1324-30.
24. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17: 350-5.
25. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalko-nium chloride-preserved, polyquad-preserved, and sof-Zia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010; 27: 837-45.
26. Liang H, Brignole-Baudouin F, Pauly A, Riancho L, Bau-douin C. Polyquad-preserved travoprost/timolol, ben-zalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther 2011; 28: 311-25.
27. Lewis RA, Katz GJ, Weiss MJ, et al, Travoprost BAC-free Study Group. Travoprost 0.004% with and without ben-zalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007; 16: 98-103.
28. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004; 26: 84-91.
29. Sit AJ, Weinreb RN, Crowston JG, Kripke D F, Liu JH. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol 2006; 141: 1131-3.
30. García-Feijoo J, de-la-Casa JMM, Castillo A, Mé-ndez C, Fernández-Vidal A, García-Sánchez J. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin 2006; 22: 1689-97.
31. Lindén C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with la-tanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 1997; 81: 370-2.
32. Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol 2001; 131: 798-9.
33. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008; 53(Suppl 1): S93-105.
34. Honrubia F, García-Sánchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latano-prost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol 2009; 93: 316-21.